You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors
|
|---|---|
| Published in |
Journal for Immunotherapy of Cancer, December 2019
|
| DOI | 10.1186/s40425-019-0815-6 |
| Pubmed ID | |
| Authors |
Ezra E. W. Cohen, Michael J. Pishvaian, Dale R. Shepard, Ding Wang, Jared Weiss, Melissa L. Johnson, Christine H. Chung, Ying Chen, Bo Huang, Craig B. Davis, Francesca Toffalorio, Aron Thall, Steven F. Powell |
X Demographics
The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 4 | 80% |
| Unknown | 1 | 20% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 4 | 80% |
| Science communicators (journalists, bloggers, editors) | 1 | 20% |
Mendeley readers
The data shown below were compiled from readership statistics for 66 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 2% |
| Unknown | 65 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 12 | 18% |
| Student > Master | 8 | 12% |
| Student > Bachelor | 7 | 11% |
| Student > Ph. D. Student | 5 | 8% |
| Other | 3 | 5% |
| Other | 4 | 6% |
| Unknown | 27 | 41% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 19 | 29% |
| Biochemistry, Genetics and Molecular Biology | 5 | 8% |
| Nursing and Health Professions | 3 | 5% |
| Agricultural and Biological Sciences | 3 | 5% |
| Immunology and Microbiology | 3 | 5% |
| Other | 6 | 9% |
| Unknown | 27 | 41% |
Attention Score in Context
This research output has an Altmetric Attention Score of 20. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 September 2022.
All research outputs
#1,848,478
of 25,540,105 outputs
Outputs from Journal for Immunotherapy of Cancer
#478
of 3,454 outputs
Outputs of similar age
#43,800
of 477,290 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#14
of 92 outputs
Altmetric has tracked 25,540,105 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,454 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.7. This one has done well, scoring higher than 86% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 477,290 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 92 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 84% of its contemporaries.